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Mast cells are tissue-resident cells with important functions in allergy and inflammation. 
Pluripotential hematopoietic stem cells in the bone marrow give rise to committed mast cell 
progenitors that transit via the blood to tissues throughout the body, where they mature. 
Knowledge is limited about the factors that release mast cell progenitors from the bone 
marrow or recruit them to remote tissues. Mouse femoral bone marrow cells were cultured 
with IL-3 for 2 wk and a range of chemotactic agents were tested on the c-kit
 

 
 population. 
Cells were remarkably refractory and no chemotaxis was induced by any chemokines tested. 
However, supernatants from activated mature mast cells induced pronounced chemotaxis, 
with the active principle identified as leukotriene (LT) B
 
4
 
. Other activation products were 
inactive. LTB
 
4
 
 was highly chemotactic for 2-wk-old cells, but not mature cells, correlating 
with a loss of mRNA for the LTB
 
4
 
 receptor, BLT1. Immature cells also accumulated in vivo in 
response to intradermally injected LTB
 
4
 
. Furthermore, LTB
 
4
 
 was highly potent in attracting 
mast cell progenitors from freshly isolated bone marrow cell suspensions. Finally, LTB
 
4
 
 was a 
potent chemoattractant for human cord blood–derived immature, but not mature, mast 
cells. These results suggest an autocrine role for LTB
 
4
 
 in regulating tissue mast cell numbers.
 
Mast cells are long-lived cells that reside in
tissues, where they play important roles in in-
flammation, angiogenesis, and wound healing.
They are principally recognized for their effec-
tor functions in allergic reactions and in host
defense to helminth parasites, but they also
have roles as sentinel cells in responses to mi-
crobial infections (1). Mast cells have Fc
 

 
R1
receptors that bind IgE with high affinity, and
recognition of polyvalent antigen triggers re-
ceptor cross-linking. This results in the release
of degranulation products and the de novo
synthesis of mediators with potent inflamma-
tory activity (e.g., smooth muscle spasmogens),
vasopermeability agents, and chemoattractants,
as well as cytokines with a range of activities.
Mast cells are derived from pluripotential
hematopoietic stem cells in the bone marrow
(2). Under the influence of growth factors,
these cells give rise to committed mast cell
progenitors. The progenitors are released from
the bone marrow into the blood from where
they localize to different tissues throughout the
body. Once in the tissues, mast cell maturation
proceeds, with local factors determining the
mature phenotype appropriate for the particu-
lar location. Two major subtypes of mast cells
have been identified: connective tissue type,
particularly localized in skin, around blood
vessels, and in the peritoneal cavity; and mu-
cosal type, which is associated with mucosal
surfaces such as those in the gut or airways.
These subtypes have a characteristic expression
of particular serine proteases (3–5). Studies in
mice have revealed important information on
the nature of mast cell progenitors and their
transit between compartments of the body, but
specific details of the mechanisms involved in
their release from the bone marrow and re-
cruitment to the tissues remain to be estab-
lished. The importance of mucosal mast cells
in certain host defense reactions to parasites
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and in allergic reactions is demonstrated by the localized
mast cell hyperplasia that occurs in the affected tissues (6, 7).
Animals lacking stem cell factor (SCF), such as the WCB6
 
F1
 
-
Sl/Sl
 
d
 
 mouse (8), or its receptor, c-kit, such as in the
WBB6
 
F1
 
-W/W
 
v
 
 mouse (2), have few tissue mast cells con-
stitutively and fail to develop mast cell hyperplasia. Thus,
SCF and its receptor are essential for mast cell maturation
and/or localization.
Studies of mast cell progenitors in tissues are difficult be-
cause of their very low numbers in situ. A minor population
of circulating c-kit
 

 
 committed mast cell progenitors has
been reported in mouse fetal blood (9). Recently, sequential
immunomagnetic isolation of adult mouse bone marrow has
revealed a 0.02% population of undifferentiated mast cells
characterized as CD34
 

 
, CD13
 

 
, c-kit
 

 
, and Fc
 

 
R1
 

 
 
 
(10).
Another approach, using limiting dilution assays, has been
used to determine the numbers of mast cell progenitors in
different tissues, including the small and large intestine, lung,
spleen, and bone marrow (11). It has also been demonstrated
that the 
 

 
4
 

 
7
 
 integrin is essential for mast cell progenitor
homing to the small intestine (11). A c-kit
 

 

 
4
hi
 

 
7
 

 
 mast cell
progenitor has been reported in mouse bone marrow 5 d af-
ter infecting the small intestine with 
 
Trichinella spiralis
 
 (12).
Loss of these cells from the bone marrow was followed by
their appearance in the blood, with mature mast cells be-
coming detectable in the gut after 3 d (12).
Analogy with the recruitment of mature leukocytes
would suggest that soluble chemoattractants, acting in con-
cert with adhesion molecules, may regulate the population
of tissues with mast cell progenitors. Such chemotactic fac-
tors may also be involved in the release of progenitors from
the bone marrow, as demonstrated previously for mature
leukocytes (13–15) and their precursors (16). Thus, we have
investigated the chemotactic responses of immature c-kit
 

 
mast cells cultured from mouse femoral bone marrow in the
presence of IL-3. Such cells have been shown to be capable
of populating tissues in vivo after intravenous injection in
mice (17). These cells were found to be remarkably selective
Figure 1. Characterization of BMMC cultures. The percentage of 
c-kit cells in the total BMMC culture (a) and the mean fluorescence 
intensity of c-kit expression on the c-kit BMMCs (b) were measured by 
flow cytometry. Data shown are SEM (n  9). (c) Representative dot 
plots showing double staining of 2-wk- (left), 6-wk- (middle), and 10-wk-old 
(right) BMMCs with anti–c-kit–PE (c-kit) and either IgE followed by anti-
IgE–FITC (top, FcR1), anti-CD34–FITC (top middle, CD34), anti-T1/ST2–
FITC (bottom middle, T1/ST2), or anti-CD13–FITC (bottom, CD13). Data 
shown are SEM (n  6). (d) The mean fluorescence intensity of 4 and 
7 integrins on c-kit BMMCs decreases from 1 to 10 wk. (e) Representa-
tive dot plots showing forward and side scatter of 2-wk- (left), 6-wk- 
(middle), and 10-wk-old (right) BMMCs. Data shown are SEM (n  4).
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in their chemotactic responses (e.g., no responses were elic-
ited by any of the chemokines tested). We investigated
whether mature mast cells release factors during activation
that are chemotactic for immature mast cells. Our evidence
demonstrates that leukotriene (LT) B
 
4
 
 is such a factor that
potently attracts mouse immature mast cells. Interestingly,
this effect is transient and is lost on cell maturation, correlat-
ing with the loss of the LTB
 
4
 
 receptor, BLT1. Human mast
cells exhibit a similar transient responsiveness. Mouse and
human immature mast cells were unresponsive, or relatively
poorly responsive, to SCF; this suggests that its receptor, c-kit,
is not efficiently linked to the locomotor machinery at an
early stage in mast cell development.
LTB
 
4
 
 was originally discovered as an arachidonate me-
tabolite that stimulates neutrophils (18) and has recently been
shown to be a chemoattractant for effector CD4
 

 
 and CD8
 

 
T-lymphocytes (19–21), acting via the high affinity receptor
BLT1. The results presented here suggest that LTB
 
4 
 
released
from activated mature mast cells may also have an important
autocrine role in regulating the release of mast cell progeni-
tors from the bone marrow and/or their recruitment into
tissues before maturation.
 
RESULTS
Effects of chemotactic agents on BM-derived 
mast cells (BMMCs)
 
Mast cells cultured in IL-3 were analyzed in terms of purity
and maturation state for up to 10 wk, with the aim of study-
ing chemotactic responses in cells of minimal maturity at a
time when numbers were such that experiments were practi-
cable. Cells were analyzed weekly by flow cytometry; results
are shown in some cases for 2-, 6-, and 10-wk-old BMMCs
(Fig. 1, c and e). After 1 wk, 
 

 
1% of cells exhibited high
c-kit expression, but this rose to 
 

 
50% by 2 wk in culture
(Fig. 1 a). At 4 wk, 
 

 
85% of cells were c-kit
 

 
, and this was
maintained up to 10 wk (Fig. 1 a). The intensity of c-kit ex-
pression was high at 1 wk; this increased until 3 wk and was
then maintained (Fig. 1 b). Identification of c-kit
 

 
 cells as
mast cells was confirmed by double labeling with antibodies
to other mast cell markers, including Fc
 

 
R1, CD34, T1/
ST2 (22), and CD13 (Fig. 1 c). Expression of Fc
 

 
R1 and
TI/ST2 did not change detectably
 
 
 
from 2 to 10 wk in cul-
ture, whereas CD34 and CD13 did not reach maximum lev-
els until 3–4 wk. Expression of the integrins 
 

 
4
 
 and 
 

 
7
 
 was
observed on 1-wk-old c-kit
 

 
 BMMCs, which was consis-
tent with the progenitor mast cells previously described as
c-kit
 

 

 
4
hi
 

 
7
 
 
 
(12). This expression decreased from 1 to 4 wk
and remained at low levels up to 10 wk in culture (Fig. 1 d).
At 2 wk in culture, the granularity of the cell population
measured as side scatter by flow cytometry was low. By 6
wk, some cells showed an increase in side scatter; at 10 wk,
most of the cell population exhibited substantial
 
 
 
granularity,
which was consistent with mature mast cells (Fig. 1 e).
Chemotactic responses of 2-wk-old BMMCs were mea-
sured using 96-well microchemotaxis plates. Migrated cells
were recovered from the lower chambers after 3 h at 37
 
	
 
C and
double stained with monoclonal antibodies to c-kit (mast cells)
and Gr-1 (a marker for the major contaminating population).
The c-kit
 

 
 cells migrated in response to SCF when present in
the lower chambers. With SCF used as the positive control in
further experiments, none of the following were found to be
chemotactic for c-kit
 

 
 cells under the conditions of our experi-
ments: (a) cytokines/growth factors (NGF, TGF-
 

 
1,
 
 activin-A,
and VEGF); (b) CC chemokines (JE [CCL2], MIP-1
 

 
 [CCL3],
RANTES [CCL5], Eotaxin-1 [CCL11], MIP-3
 
 
 
[CCL19],
and MEC [CCL28]); (c) CXC chemokines (KC and MIP-2
[orthologues of the human GRO family], MIG [CXCL9], IP-
10 [CXCL10], I-TAC [CXCL11], and SDF-1
 

 
 [CXCL12]);
and (d) peptides (fMLP, bradykinin, and substance P). In the
same assays, Gr-1
 

 
 cells present in the upper chambers migrated
in response to KC, MIP-2, MIP-1
 

 
, JE, RANTES, and fMLP
(e.g., KC at 0.1, 1, and 10 nM induced the migration of 49 
 

 
29, 118 
 

 
 35, and 219 
 

 
 34 Gr-1
 

 
 cells, respectively, com-
pared with 9 
 

 
 4 cells for the control; 
 
n 
 

 
 4 experiments).
 
Migration of 2-wk-old BMMCs in response to mast cell 
activation products
 
We investigated the possibility that mature mast cells, on ac-
tivation, release a chemoattractant for immature cells. 10-
Figure 2. Activated mast cell supernatants induce migration of 
2-wk-old BMMCs. 10-wk-old BMMCs were either nonactivated (open 
bars) or activated through FcR1 cross-linking for 2 h (closed bars), and 
cell-free supernatants (undiluted [NEAT] or diluted at 1:3, 1:9, and 1:27) 
were added to the lower wells of a 96-well chemotaxis plate. BMMCs cul-
tured for 2 (a) or 10 wk (b) were added to the top wells. After a 3-h incu-
bation, migrated cells were removed from the wells, double stained with 
anti–c-kit–PE and anti–Gr-1–FITC, and c-kit BMMCs were counted by 
flow cytometry. No cells migrated to assay buffer alone. Data are mean  
SEM (n  3) for 10-wk-old cultures to generate the supernatants.
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wk-old BMMCs were passively sensitized with IgE and acti-
vated by the specific antigen, DNP, conjugated to human
serum albumin (HSA). Supernatants were then tested in che-
motaxis assays on 2-wk-old immature and 10-wk-old ma-
ture BMMCs. Supernatants from nonactivated cells induced
negligible chemotaxis; however, supernatants from activated
cells induced pronounced migration of 2-wk-old cells with a
bell-shaped concentration–response curve and a maximal re-
sponse at a 1:9 dilution (Fig. 2 a). In comparison, only very
weak responses were obtained using 10-wk-old cells in the
chemotaxis assay (Fig. 2 b).
 
Identification of chemoattractant activity in supernatants 
from activated mast cells
 
Supernatants from activated and nonactivated 10-wk-old
BMMCs were applied to reverse phase HPLC and fractions
were collected for chemotaxis assay on 2-wk-old BMMCs.
Virtually all the chemotactic activity from activated mast cell
supernatants was present in fraction 20 (41% acetonitrile
[ACN]), with a small amount in fraction 21 (Fig. 3). No
chemotactic activity was detectable in the other fractions or
in any of the fractions from the nonactivated cell superna-
tants (Fig. 3). Known products of mast cell activation were
subsequently run through the same column as authentic
standards and their retention times were recorded by absor-
bance at 280 nm (for LTs) or 200 nm (for non-LT stan-
dards). LTB
 
4
 
 eluted with a retention time indistinguishable
from that of the activated mast cell–derived activity (fraction
20), in contrast to the peptido-LTs, LTC
 
4
 
 (fraction 17/18),
LTD
 
4
 
 (fraction 21), and LTE
 
4
 
 (fraction 21/22). As shown in
Fig. 3, other mast cell activation products—PGD
 
2
 
, hista-
mine, and 5-hydroxytryptamine—eluted much earlier in the
gradient than the mast cell–derived chemotactic activity, as
did the 20-hydroxy metabolite of LTB
 
4
 
. Thus, the chemo-
tactic activity in the supernatants of activated mast cells coe-
luted with authentic LTB
 
4
 
 and not with any other known
product of acute activation. Furthermore, ELISA of the
HPLC fractions of activated mast cell supernatants showed
that the majority of LTB
 
4
 
 immunoreactivity was in fraction
20 (10.6 nM) with a smaller amount (4.6 nM) in fraction 21.
The generation of chemotactic activity for 2-wk-old
BMMCs was abolished by pretreating mature mast cells with
MK-886, an inhibitor of 5-lipoxygenase (5-LO) activating
protein before activation (Fig. 4 a). Supernatants were assayed
on 2-wk-old BMMCs as before. MK-886 at 100 nM re-
Figure 3. HPLC of the mast cell progenitor chemoattractant activity 
released by mature mast cells. 10-wk-old BMMCs were either activated 
via FcR1 cross-linking for 2 h (top), or nonactivated (bottom), and the 
supernatants applied to reversed phase HPLC. Fractions were tested for 
chemotaxis of c-kit 2-wk-old BMMCs. This result is representative of two 
independent experiments using supernatants from different 10-wk-old 
BMMC cultures tested on different 2-wk-old cultures. Arrows indicate the 
elution of LT (B4, C4, D4, E4, and 20-hydroxy-LTB4) and non-LT (histamine 
[H], 5-hydroxy tryptamine [5-HT], and PGD2) standards.
Figure 4. LTB4 is chemotactic for 2-wk-old BMMCs. (a) 10-wk-old 
BMMCs were activated through FcR1 cross-linking for 2 h after pretreat-
ment for 10 min at 37	C with a 5-LO inhibitor (black bars, MK-886), vehicle 
alone (gray bar, V), or buffer (open bar, control). Cell supernatants were 
added to the lower wells of chemotaxis plates at a 1:9 dilution and 2-wk-old 
BMMCs were added to the upper wells. After 3 h, migrated cells were re-
moved from the wells and c-kit BMMC migration was counted. MK-886 
inhibited migration of 2-wk-old BMMCs at 100 nM and 1 
M (P  0.05). 
Data are SEM (n  3). (b) SCF (0.1–100 nM), LTB4, LTC4, LTD4, LTE4, and 
PGD2 (0.1–1,000 nM) were tested for their ability to induce migration of 
2-wk-old BMMCs. LTB4 and SCF induced migration of 2-wk-old BMMCs, 
but LTC4, LTD4, LTE4, and PGD2 induced no migration. Data are mean  SEM 
for LTB4 and SCF (n  8), LTC4 (n  4), and LTD4, LTE4, and PGD2 (n  3). LTB4 
(c) or SCF (d) were added to either the top or the bottom wells of a 96-well 
chemotaxis plate and 2-wk-old BMMCs were added to the top wells. 
Migrated cells were removed and c-kit BMMCs counted. Data are mean  
SEM (n  3). No cells migrated to assay buffer alone in any experiment.
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duced chemotactic activity substantially, whereas 1 
M gave
complete inhibition. Supernatants from untreated activated
mast cells contained 46 nM LTB4 (3.1 ng/106 cells), mea-
sured by ELISA, which was reduced to 4 nM and 0.06 nM
with 100 nm and 1 
M MK-886, respectively.
Comparison of the chemotactic activities of lipid mediators 
on 2-wk-old BMMCs
The chemotactic activity of lipid mediators tested on 2-wk-
old BMMCs was compared with that of SCF (Fig. 4 b).
LTB4 had a high potency and efficacy. SCF had a much
lower efficacy and the peptido-LTs C4, D4, and E4 were in-
active. In addition, PGD2 (Fig. 4 b), 5-hydroxytryptamine,
histamine, and platelet activating factor (unpublished data)
were also inactive as chemotactic agents on these cells. 20-
hydroxy-LTB4, a metabolite of LTB4, exhibited chemotactic
activity, but was 100-fold less potent than its parent (unpub-
lished data). The c-kit cells migrated in response to both
LTB4 and SCF when the agents were present in the lower
chambers, but not when added with the cells above the fil-
ter, characteristic of a chemotactic response requiring a gra-
dient, rather than a chemokinetic response, representing in-
creased random movement (Fig. 4, c and d). As well as being
active as a chemoattractant for c-kit cells cultured for 2 wk
in IL-3, LTB4 was also active on cells cultured for 2 wk in a
combination of IL-3 and SCF (unpublished data).
Comparison of the chemotactic effect of LTB4 on 
2- and 10-wk-old BMMCs
The chemotactic effect of LTB4 was examined on BMMCs at
different stages of maturity. LTB4 was highly potent and effi-
cacious on immature mast cells cultured for 2 wk. By 6 wk,
chemotactic responses were very weak and remained so at 10
wk (Fig. 5 a). In contrast, no notable decrease in responsive-
ness to SCF was observed as the cells matured (Fig. 5 b).
The loss of responsiveness to LTB4 with mast cell matu-
ration was associated with a reduction in mRNA expression
of BLT1. Cells cultured for 2, 6, and 10 wk were purified by
positive selection using CD117 (c-kit) immunomagnetic
beads. Fig. 6 a shows, using RT-PCR, the decrease in
mRNA as the mast cells matured. Using real-time PCR
analysis, 2-wk-old BMMCs were shown to express fourfold
more BLT1 mRNA than 6-wk-old cells, and 10-fold more
than 10-wk-old cells (Fig. 6 b).
Chemotactic effect of LTB4 on freshly isolated cell 
suspensions from mouse femoral bone marrow
Fresh cell suspensions of mouse femoral bone marrow were
tested in 96-well chemotaxis assays using LTB4 and SCF at
concentrations effective on cultured BMMCs (Fig. 4 b). Af-
ter 3 h of incubation, migrated cells were recovered from the
lower chambers and cultured for 2 wk in IL-3, IL-9, SCF,
and TGF-1, a medium favoring rapid maturation toward a
mucosal mast cell phenotype (23, 24) to enable quantitation
of mast cell numbers by their content of mast cell–specific
Figure 6. Expression of BLT1 mRNA in c-kit 2-wk-old BMMCs. 
(a) BLT1 mRNA expression, analyzed by RT-PCR and compared with the 
housekeeping gene GAPDH, was higher in 2-wk-old than in either 6- or 
10-wk-old BMMCs. The result is representative of three independent ex-
periments using RNA isolated from separate cell cultures. (b) Real-time 
PCR analysis of BLT1 mRNA expression in 2-, 6-, and 10-wk-old BMMCs. 
Fold increases in BLT1 mRNA in BMMCs were normalized to GAPDH, with 
an internal 18S control to which both GAPDH and BLT1 were normalized. 
2-wk-old BMMCs expressed more BLT1 mRNA than 6- or 10-wk-old 
BMMCs (P  0.05). Data are mean  SEM (n  3) using RNA isolated 
from separate cell cultures.
Figure 5. LTB4 is a more efficacious chemoattractant for 2-wk-old 
than for 6- or 10-wk-old BMMCs. LTB4 (a) or SCF (b) were added to the 
bottom wells of a 96-well chemotaxis plate and 2-, 6-, and 10-wk-old 
BMMCs were added to the top wells. After 3 h, migrated cells were re-
moved, stained, and c-kit BMMCs were counted. No cells migrated to 
assay buffer alone. Data are mean  SEM for 2- and 10-wk-old BMMCs 
(n  6), and 6-wk-old BMMCs (n  4).
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proteases. Cells were then lysed by freeze-thawing and the
released murine mast cell proteases (mMCP)-1 and -2 were
quantitated using ELISA. Although the number of mast cell
progenitors in the bone marrow was low (25) and, thus, the
migrating cells were few in number, this system provided
amplification to enable a measurement in proportion to the
number of migrated mast cell progenitors. LTB4 induced a
concentration-related increase in both mMCP-1 and -2,
with a maximal effect, seen at 10 nM (Fig. 7, a and b). Inter-
estingly, SCF failed to induce a detectable response; no pro-
teases were detected nor were any cells observed microscop-
ically in the cultures before the lytic step (Fig. 7, a and b).
Chemokines acting via CCR3, Eotaxin-1, and CXCR2,
KC and MIP-2, also failed to demonstrate a chemotactic ef-
fect in this system (unpublished data).
Localization of prelabeled BMMCs in vivo after intradermal 
(i.d.) injection of LTB4
2-wk-old 5-chloromethylfluorescein diacetate (CMFDA)–
labeled BMMCs were either negatively selected by immu-
nomagnetic bead separation to remove the contaminating
Gr-1 cells, or c-kit BMMCs were positively selected. The
isolated cells were injected intravenously into mice, followed
by i.d. injections of 150 pmol LTB4 or vehicle control at
separate sites in the dorsal skin of each mouse. Animals were
killed 1 h after i.d. injections, and the skin was removed and
processed for microscopy. Negatively selected CMFDA-
labeled  BMMCs accumulated at the LTB4 injection sites,
compared with the few cells present in the vehicle control
injection sites (Fig. 8, a–c; P  0.05). The same was seen for
positively selected CMFDA-labeled  BMMCs (Fig. 8 d),
with 23.2  4.7 cells/50 mm2 accumulating at the LTB4 site
compared with 9.4  1.9 cells/50 mm2 accumulating at the
vehicle control site (n  5, P  0.05). The majority of CM-
FDA-labeled  BMMCs observed were extravascular. Fig. 8
(b–d) shows representative images of CMFDA-labeled  BM-
MCs detected in the skin by confocal microscopy.
Chemotactic effect of LTB4 on immature mast cells 
derived from human umbilical cord blood–derived 
mast cells (CBMCs)
Mast cells were cultured from human umbilical cord blood
using an established method (26). A uniform population of
c-kit cells was evident at 4 wk that exhibited the charac-Figure 7. Freshly isolated bone marrow cells that migrate in response 
to LTB4 develop into mMCP-1– and -2–expressing mature mast 
cells. LTB4 and SCF were added to the bottom wells of a 96-well chemo-
taxis plate, and freshly isolated bone marrow cells were added to the top 
wells. After a 3-h incubation, migrated cells were cultured for 14 d in the 
presence of TGF-1, SCF, IL-3, and IL-9. On day 14, cells were frozen, lysed, 
and assayed for levels of mMCP-1 (a) and -2 (b). LTB4 -induced migration 
of cells that developed into mMCP-1– and -2–expressing cells (mast cells), 
but SCF did not induce migration of this cell population. Migration to 
buffer alone gave mMCP-1 and mMCP-2 values below the detection limits 
of the assays (0.04 ng/ml). Data are mean  SEM (n  3) for different 
bone marrow cell preparations.
Figure 8. Localization of prelabeled BMMCs in mouse skin in re-
sponse to i.d. LTB4. (a) Increased numbers of CMFDA-labeled  BMMCs 
(negative selection) in skin injected with 150 pmol LTB4 compared with vehi-
cle control sites. Data are mean  SEM (n  4; P  0.05). (b–d) Representa-
tive confocal micrographs of whole-mount mouse skin. Prelabeled CMFDA-
labeled BMMCs are green in skin samples counter-stained with GSL-1 
Isolectin B4, staining endothelium, and neutrophils red. (b) Vehicle control 
(negative BMMC selection). (c) LTB4 injection site showing extravascular 
CMFDA-labeled  BMMCs and capillaries of 4–6-
m diameter (negative 
BMMC selection). (d) LTB4 injection site showing CMFDA-labeled  BMMCs 
migrating from venules of 18–25 
m (positive BMMC selection). Bars, 20 
m.
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teristics of immature mast cells, such as detectable but low
FcR1 expression, low side scatter, and lack of specific
markers for other cell types, including CD14 (monocytes),
CD16 (neutrophils), and CD123 (basophils). In subsequent
weeks of culture, a population of mast cells with a more ma-
ture phenotype was also observed, with higher expression of
both c-kit and FcR1, but no expression of CD14, CD16,
or CD123, and increased side scatter, indicating increased
granularity. By 8–9 wk, only the more mature c-kithigh
FcR1high mast cell population was present, also in agree-
ment with Ochi et al. (26). The two populations are illus-
trated in Fig. 9 (a–e) in a representative 7-wk-old culture.
Chemotaxis of the cultured cells was investigated between 5
and 7 wk when both the c-kit and c-kithigh mast cell popu-
lations were present. The proportions of the two populations
varied between cord blood preparations and over the 5–7-
wk period, from 32 to 80% (56.2  8.3%, n  5) c-kit and
20 to 68% (43.8  8.3%, n5) c-kithigh cells. Chemotaxis
experiments were performed in 96-well plates using the
mixed cultured cells, and the numbers of migrated cells from
each of the two populations were determined according to
intensity of c-kit expression by flow cytometry. LTB4 was a
highly potent and efficacious chemoattractant for the imma-
ture c-kit mast cell population (Fig. 9 f ), but the mature
c-kithigh mast cells were unresponsive (Fig. 9 g). In contrast,
the mature cells responded to SCF, albeit with low efficacy
(Fig. 9 g), whereas the immature cells showed no response
(Fig. 9 f ).
DISCUSSION
Cell migration is of critical importance at several stages dur-
ing the life history of the mast cell. Committed mast cell
progenitors, derived from pluripotential stem cells in the
bone marrow stroma, must first transit toward and through
the sinus endothelium to gain access to the general circula-
tion. The progenitors then attach to and migrate through the
microvascular endothelium of peripheral tissues. There, un-
der the influence of local factors, the progenitors begin to
mature and can migrate away from blood vessels toward
their final destination, where they exhibit a phenotype char-
acteristic of their location. We are particularly interested in
mucosal mast cells whose numbers increase markedly in ap-
position to epithelial surfaces in response to allergic stimuli, a
process associated with the migration of cells from the lam-
ina propria and thought to include recruitment from mi-
crovessels in this region.
To investigate potential chemoattractant molecules in-
volved in progenitor recruitment from the blood, we cul-
tured mouse bone marrow cells with IL-3 and measured their
responses in chemotaxis chambers using cells as immature as
possible at a time when c-kit cells were of sufficient num-
bers for study. Under the conditions of our experiments,
these immature c-kit cells were remarkably unmoved by a
range of known chemotactic agents. The cells responded
chemotactically to SCF but not to other factors tested, such as
chemokines acting through CXCR2 or CCR3, receptors
previously described on mast cells (26–28). We were sur-
prised at this lack of responsiveness, which contrasts with
many reports of chemotactic responses of mast cells to a range
of mediators, including chemokines (27, 29–33). We believe
that this difference is largely attributable to the stage of matu-
rity of the cells as we concentrated on very immature mast
cells, but differences in methodology may also play a part.
Figure 9. LTB4 induces migration of immature, but not mature, 
human CBMCs. (a) Representative histogram of CBMCs cultured for 7 wk 
and stained with anti–human c-kit–PE (open histogram) or isotype control 
(shaded histogram). Two populations of c-kit–expressing mast cells can be 
seen (c-kit and c-kithigh). (b and c) Histograms showing that FcR1 ex-
pression (open histogram) is detectable above the control antibody (shaded 
histogram) on both c-kit and c-kithigh cells. (d and e) Representative dot 
plots showing forward and side scatter of the c-kit and c-kithigh cells. 
Migration of 5–7 wk c-kit (f) and c-kithigh (g) mast cells to LTB4 and SCF. 
Migrated cells were stained with anti–human c-kit–PE and anti–human 
CD14–FITC and counted. Migration to assay buffer alone was 4.5  1.4% 
c-kit cells and 0.7  0.15% c-kithigh cells. Data are mean  SEM (n  5) 
using cells cultured from separate donors.
LTB4 IS CHEMOTACTIC FOR MAST CELL PROGENITORS | Weller et al.1968
In light of the mast cell hyperplasia observed in sensitized
individuals exposed to allergen, we investigated whether ac-
tivation of mature mast cells by cross-linking their FcR1
results in the production of a chemoattractant for immature
mast cells. We demonstrate that immature mast cells cultured
for 2 wk from mouse bone marrow are highly responsive in
vitro to the chemotactic effect of LTB4 released on activa-
tion of mature mast cells. In addition, immature cells were
able to accumulate in response to intradermally injected
LTB4 in vivo. The results shown in Fig. 7 indicate that mast
cell progenitors in fresh bone marrow also respond highly to
LTB4 in vitro, although it is not possible from this study to
determine precisely when the receptor is first expressed. The
responsiveness to LTB4 is transient and is lost as the cells ma-
ture, correlating with the loss of mRNA for BLT1. These
results are consistent with those in a recent study showing a
weak chemotactic effect of LTB4 on BMMCs (chemotactic
index of 2) as cells of 4–6 wk in culture were used (34).
Interestingly, results obtained with human CBMCs were
very similar to those obtained with mouse BMMCs. Human
immature mast cells were highly responsive to LTB4, an ef-
fect lost on maturation.
The lack of responses of mature mast cells to LTB4 may
explain why this mediator has previously been identified only
as a product of this cell rather than as its chemoattractant.
Human and mouse mast cells have been reported to produce
between 1 and 4 ng LTB4/106 cells after FcR1 cross-linking
(35–37). Accordingly, we found that our activated BMMC
supernatants contained 3.1 ng LTB4/106 cells, and nonacti-
vated mast cells produced no detectable LTB4. BLT1 expres-
sion has been investigated previously on mast cells in tissues
during allergic reactions, but was reported to be very low
(38). In contrast, cysteinyl LT receptors are expressed on
mast cells in tissues during allergic disease and by human CB-
MCs (38–40). The observation that immature mast cells re-
spond strongly to a major activation product of mature cells
may be more than a coincidence. The evanescent responsive-
ness of mast cells to LTB4, correlating with transient BLT1
mRNA expression, strongly implies an important function at
a critical stage in their life history. We suggest that LTB4 pro-
duced by activated mast cells in tissues is able to recruit circu-
lating mast cell progenitors and contribute to mast cell hyper-
plasia at sites of allergic reactions (41, 42). Furthermore,
LTB4 may contribute to the movement of immature mast
cells from the lamina propria to the epithelium of affected tis-
sues. Once at their final location, the mature cells then be-
come insensitive to LTB4 because of the loss of BLT1. The
reason for this may be to ensure that mature mast cells do not
congregate exclusively at areas of focal allergen stimulation,
leaving adjacent areas of epithelium depleted.
Recruitment of mast cell progenitors would also be ex-
pected to result from LTB4 production by cells other than
mast cells, e.g., neutrophils. Irrespective of the cellular
source of LTB4, progenitor recruitment would only result in
population with mature cells if the appropriate maturation
factors were present. The general mechanisms we describe
may also operate in response to foreign organisms; e.g., hel-
minths and microorganisms. It will be of interest to investi-
gate the importance of these mechanisms in disease models
in which mast cells have a critical role. One example is a
mouse autoimmune arthritis model in which mast cells are
obligatory (43). LTB4 may drive both the recruitment of
mast cell progenitors and neutrophils in this model. Simi-
larly, a mouse model of experimental allergic encephalomy-
elitis is described as mast cell dependent (44–46), and an
LTB4 receptor antagonist has been shown to suppress disease
pathology in this model (47).
Chemoattractants generated at sites of inflammation serve
an important function in recruiting inflammatory cells. These
same mediators, having gained access to the general circula-
tion, can act remotely and release leukocytes from the bone
marrow by establishing a chemotactic gradient across the sinus
endothelium (15), as exemplified by eotaxin-1, that can release
both mature eosinophils and their progenitors (14, 16). The
experiments described here using freshly isolated bone marrow
cell suspensions demonstrate that mast cell progenitors in the
marrow can respond to low concentrations of LTB4. Thus,
circulating LTB4 may induce progenitor release in vivo. Al-
though c-kit, the receptor for SCF, is a classical marker for
mast cells, it may be important that fresh mouse mast cell pro-
genitors and the immature human CBMCs were shown to be
unresponsive to SCF as a chemoattractant. SCF clearly has a
vital role in mast cell development, but we suggest that this
factor may not have a role in releasing mast cell progenitors
from the bone marrow or their recruitment into tissues. In-
deed, SCF gradients established in the bone marrow as the re-
sult of local production in the stroma would be in the wrong
direction to mediate movement of cells into sinuses by chemo-
taxis, although theoretically such gradients could be reversed
by elevation of circulating SCF as a consequence of production
in other tissues. The observation that the mouse bone marrow
cells cultured for 2 wk with IL-3 did respond chemotactically
to SCF (albeit with relatively low efficacy) suggests that these
cells are a little more advanced in maturity than the bone mar-
row progenitor mast cells; these 2-wk-old cells retain respon-
siveness to LTB4, but now have the c-kit receptor coupled to
the locomotor machinery. Both mouse and human mature
mast cell did respond chemotactically to SCF, so it is possible
that this mediator is involved with relocating mature or matur-
ing mast cells within tissues once the progenitors have been re-
cruited. This would be an additional function to the critical
role of SCF in mast cell proliferation and maturation.
Thus, LTB4 may serve the function of an autocrine me-
diator produced by activated mast cells, mediating the supply
of their progenitors to the tissue. This may be important in
the mast cell hyperplasia that is overt in allergic reactions and
responses to helminth parasite infections. If this is the case, it
would follow that interventions resulting in an increase in
mast cell activation would increase tissue mast cell numbers.
Such an increase in numbers has been observed in a recent
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study after deletion of RabGEF1, which is a component of a
negative feedback pathway that makes mast cells more
readily activated (48). Rabgef1/ mice showed spontaneous
inflammation in the skin associated with mast cell degranula-
tion and increased mast cell numbers (48). Alternatively, in-
terventions aimed at suppressing the production or actions of
LTB4 e.g., using 5-LO inhibitors or BLT1 antagonists, may
suppress mast cell hyperplasia and, thus, be of benefit in al-
lergic diseases, such as allergic rhinitis and asthma.
MATERIALS AND METHODS
Reagents. BSA, PBS, 2-ME, Histopaque 1077, human TGF-1, FMLP,
bradykinin, Substance P, anti–DNP IgE (clone SPE-7), HSA-DNP, and 0.22-

m spin filters were obtained from Sigma-Aldrich. TFA (peptide synthesis
grade) was obtained from Rathburn, and ACN (far UV grade for HPLC) was
obtained from Merck. RPMI 1640, DMEM, Hepes, penicillin, streptomycin,
L-glutamine, FBS, fungizone, sodium pyruvate, and nonessential amino acids
were purchased from Invitrogen. PE–rat anti–mouse CD117 (2B8), FITC–rat
anti–mouse IgE (R35-72), FITC–rat anti–mouse CD34 (RAM 34), FITC–rat
anti–mouse Gr-1 (RB6-8C5), FITC–rat anti–mouse CD13 (R3-242), rat anti–
mouse CD16/32 (2.4G2), PE–mouse anti–human CD117 (YB5.B8), FITC–
mouse anti–human CD14 (M5E2), FITC–mouse anti–human CD16 (3G8),
Cy5–mouse anti–human CD123 (9F5), biotin–rat anti–mouse 4 (R1-2),
FITC–rat anti–mouse 7 (M293), the appropriate isotype controls, and FACS-
Flow were obtained from BD Biosciences. FITC–rat anti–mouse T1/ST2
(2.4G2) was purchased from Morwell Diagnostics GmbH, and polyclonal rab-
bit anti–human FcR1 was obtained from Upstate Ltd. Alexa 568–conjugated
GSL-1 isolectin B4, AlexaFluor 488 goat anti–rabbit IgG (A-11008), TO-
PRO-3, and Cell Tracker green CMFDA were purchased from Molecular
Probes. All eicosanoids were obtained from Cayman Chemical. Murine IL-3,
SCF, VEGF, human SCF, IL-6 and IL-10, and all chemokines were purchased
from PeproTech. Murine IL-9 and human Activin A were obtained from
R&D Systems. Murine NGF was purchased from Promega. All microbeads
were obtained from Miltenyi Biotec. RNeasy mini kit, HotStar Taq DNA
Polymerase, and Omniscript Reverse Transcriptase were obtained from
QIAGEN. TaqMan universal PCR mastermix, BLT1, GAPDH, and 18S-spe-
cific primers (Assays-on-Demand), and the sequence detection system were
(model ABI Prism 7700) purchased from Applied Biosystems.
Mouse BMMC culture. Murine BMMCs were obtained by culture of
BALB/c femoral BM cells at 5  105 cells/ml in RPMI 1640 with 10%
FBS, 50 
M 2-ME, 2 mM L-glutamine, 100 U/ml penicillin, 100 
g/ml
streptomycin, and 5 ng/ml murine IL-3. BMMC cultures were maintained
for up to 10 wk at 37	C in 5% CO2. The flask was replaced weekly for up
to 3 wk to remove adherent cells, with weekly replacements of half the me-
dium throughout. An aliquot of cells was taken at weekly intervals for im-
munofluorescence staining. In some experiments, BM cells were cultured
with 15 ng/ml SCF in addition to IL-3 (28).
Human CBMC culture. Human mast cells were derived from heparin-
treated umbilical cord blood obtained after routine deliveries, according to
the method of Ochi et al. (26), with minor modifications. Whole blood was
diluted 1:3 with RPMI 1640 and centrifuged through Histopaque 1077 to
isolate the mononuclear cells. Residual erythrocytes were removed by hy-
potonic lysis, and the mononuclear cells were resuspended in RPMI 1640
with 10% FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100
U/ml penicillin, and 100 
g/ml streptomycin. The cells were seeded at 106
cells/ml and cultured in the presence of 100 ng/ml SCF, 50 ng/ml IL-6,
and 10 ng/ml IL-10. Cells were cultured for up to 8 wk, and the culture
medium and flask were replaced weekly. An aliquot of cells was taken at
weekly intervals for immunofluorescence staining.
Cell surface immunofluorescence and flow cytometry. BMMCs or
CBMCs were resuspended at 2–5  106 cells/ml in ice-cold staining buffer
(PBS, 0.1% sodium azide, and 0.5% BSA) containing either anti–mouse
CD16/32 or goat IgG, respectively, to block Fc receptors. After a 10-min
incubation on ice, specific mAbs were added at saturating concentrations
and incubated for a further 20–30 min in the dark. Cells were then washed,
resuspended in FACSFlow containing TOPRO-3 (1:10,000, to identify
dead cells), and analyzed on a flow cytometer (model FACSCalibur; BD
Biosciences). For FcR1 staining, after Fc receptor blocking, BMMCs were
incubated with anti-DNP IgE and then FITC-anti–mouse IgE. CBMCs
were incubated with polyclonal rabbit anti-FcR1, followed by AlexaFluor
488 goat anti–rabbit IgG (1:1,000).
Mouse BMMC chemotaxis. Chemotactic responses of BMMCs were
examined using 96-well chemotaxis plates (ChemoTx) with 5-
m pore size
polycarbonate filters. 20 
l of BMMCs were added to the top wells at 2 
106 cells/ml in RPMI 1640 with 25 mM Hepes and 0.1% BSA (assay
buffer), and 30 
l of agonist or buffer was added to the lower wells. After a
3-h incubation at 37	C, migrated cells were removed, the wells washed
with 25 
l of assay buffer, and stained with PE-anti–mouse c-kit (1:130)
and FITC-anti–mouse Gr-1 (1:160) for 10 min at 22	C to distinguish the
mast cells from nonmast cells. 100 
l FACSFlow containing 1:10,000 TO-
PRO-3 was added to the cells before counting by flow cytometry. In some
assays, the activation products from mature BMMCs were added to the
lower wells. To investigate chemokinesis, BMMCs were mixed with ago-
nist before addition to the upper assay chamber and migration to the buffer
was determined. Assays were performed in duplicate, and results were ex-
pressed as the absolute number of cells migrating.
Mouse freshly isolated BM cell chemotaxis. Chemotaxis of freshly
isolated BM cells was measured in a similar way to the cultured BMMCs,
except that 20 
l BM cells at 107 cells/ml were added to the upper wells of
chemotaxis plates immediately after isolation from femurs and aspiration
through a 19-gauge needle. Migrated cells were removed and cultured for
up to 14 d in DMEM with 10% FBS, 2 mM L-glutamine, 100 U/ml peni-
cillin, 100 
g/ml streptomycin, 2.5 
g/ml fungizone, 1 mM sodium pyru-
vate, 1 ng/ml TGF-1, 1 ng/ml murine IL-3, 5 ng/ml mIL-9, and 50 ng/
ml mSCF (24). Assays were performed in quadruplicate and, after cell lysis,
cells were enumerated by specific ELISAs for mMCP-1 and -2 (49, 50).
In vivo mast cell tracking. 2-wk-old BMMCs (2  107 cells/ml) were
labeled with 25 
M Cell Tracker Green CMFDA for 40 min at 37	C. Cells
were purified by immunomagnetic separation by either negative selection
using Gr-1 FITC followed by anti-FITC microbeads, to remove Gr-1
contaminating cells, or by positive selection using anti-CD117 (c-kit) mi-
crobeads. The isolated cells (106 cells/BALB/c mouse) were administered
by tail vein injection 5 min before i.d. injections into dorsal skin of 50 
l
LTB4 in Tyrode’s solution (150 pmol/site) and vehicle control in each
mouse. Mice were killed 1 h after i.d. injection. The skin was removed and
fixed in 4% paraformaldehyde for 24 h. A quarter segment from an 8-mm-
diameter biopsy (Schuco International) was whole mounted in a hardset
mounting medium (VECTASHIELD; Vector Laboratories) for examina-
tion by standard epifluorescence microscopy. The number of CMFDA
cells in each one fourth skin biopsy was counted. A second quarter segment
of each skin biopsy was counterstained with 10 
g/ml Alexa 568–conju-
gated GSL-1 isolectin B4, which is a marker for mouse endothelial cells and
neutrophils (unpublished data). This tissue was then whole mounted and
examined by confocal microscopy using a TCS NT system (Leica). Home
Office guidelines for animal welfare based on the Animals (Scientific Proce-
dures) Act 1986 were strictly observed.
Human CBMC chemotaxis. CBMCs cultured for 5–7 wk were used to
measure chemotaxis of human mast cells in the same way as BMMCs, ex-
cept that 20 
l of cells at 106 cells/ml were used. The mast cells were iden-
tified by staining with PE-anti–human c-kit (1:100) and FITC-anti–human
CD14 (1:100) for 10 min at 22	C before diluting with FACSFlow contain-
ing TOPRO-3 and counted. Assays were performed in duplicate, and the
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migration of c-kit or c-kithigh mast cells was expressed as a percentage of
the total c-kit or c-kithigh cells added to the wells, respectively.
Mast cell activation. Mature (10 wk) BMMCs (5  106 cells/ml) were
incubated with 10 
g/ml anti-DNP IgE for 1 h at 37	C. Cells were
washed in RPMI 1640 with 0.1% BSA, resuspended in HSA-DNP at 30
ng/ml, and incubated for 2 h at 37	C. Some cells were left untreated, or
treated with either anti-DNP IgE or HSA-DNP alone to control for basal
secretion of chemoattractant mediators. The supernatants were collected by
centrifugation through a 0.22-
m filters. Supernatants were either used un-
diluted (NEAT) or diluted at 1:3, 1:9, or 1:27 into RPMI 1640 with 0.1%
BSA. In some assays, cells were preincubated with MK-886 (5-LO inhibi-
tor; Alexis Biochemicals) for 10 min at 37	C before activation, along with
DMSO-only controls (vehicle) and cells that were treated with neither
MK-886 nor DMSO.
Reverse phase HPLC. 400 
l of activated or nonactivated 10-wk-old
mast cell supernatants, adjusted to pH 2.0 with 20% TFA and further di-
luted in 0.08% TFA, pH 2.0, or 500 pmol of eicosanoid standards, 400
nmol histamine, and 40 nmol 5-hydroxytryptamine in 0.08% TFA were ap-
plied to a 
RPC C2/C18 PC 3.2/3 column (Pharmacia Smart System; GE
Healthcare). The flow rate was one column volume (240 
l)/min in 0.08%
TFA, and the gradient was started 15 min after sample injection: 0–30%
ACN at 5% ACN/min, 30–50% ACN at 1% ACN/min, and 50–100%
ACN at 5% ACN/min. Fractions were collected from the start of the gradi-
ent (2-min fractions for 0–10 min, 0.5-min fractions for 10–22 min, and
2-min fractions for the remainder of the gradient into carrier BSA), freeze-
dried, and dissolved in 400 
l RPMI 1640 with a final concentration of
0.1% BSA for bioassay and ELISA.
ELISA. LTB4 was quantified using a specific ELISA kit (R&D Systems)
with a detection limit of 60 pM.
RT-PCR. 2-, 6-, and 10-wk-old BMMCs were isolated with anti–mouse
CD117 (c-kit) immunomagnetic beads and total RNA was extracted using
an RNeasy mini kit. First strand cDNA was generated from 0.5 
g of total
RNA using Omniscript Reverse Transcriptase with oligodeoxythymi-
dine12-18 primers. PCR was performed using primers for mouse BLT1
(available from GenBank/EMBL/DDBJ under accession no. AF044030)
5-TAAAGTCTTCCATCTGCTCTTCGAA-3 and 5-ACTTCGAA-
GACTCAGGAATGGTGGA-3 or a using GAPDH control primer set.
PCR products were generated using HotStarTaq DNA Polymerase and re-
solved on a 1% agarose gel containing 0.025 
g/ml ethidium bromide.
Real-time PCR analysis. Total RNA was extracted from purified BM-
MCs as described in the RT-PCR section and cDNA was synthesized using
the SuperScript First-Strand Synthesis System (Invitrogen) with both oli-
godeoxythymidine and random hexamer primers. 25-
l PCR procedures
were performed in triplicate using the sequence detection system (model
ABI Prism 7700), with TaqMan universal PCR mastermix and BLT1,
GAPDH, and 18S specific primers. Samples were standardized to 18S, and
BLT1 mRNA was quantified using the comparative threshold for detection
method (http://appliedbiosystems.com).
Statistics. The data are expressed as mean  SEM. Statistical differences
between groups of three or more was estimated using a Kruskal Wallis test
with pairs of groups compared with Dunn’s multiple comparison test. For
groups of two, the Mann-Whitney test was used. P  0.05 was considered
significant.
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